In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $15.91 in the prior trading day, Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) closed at $15.79, down -0.75%. In other words, the price has decreased by -$0.75 from its previous closing price. On the day, 0.91 million shares were traded. CNTA stock price reached its highest trading level at $16.05 during the session, while it also had its lowest trading level at $15.56.
Ratios:
Our goal is to gain a better understanding of CNTA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.12 and its Current Ratio is at 10.12. In the meantime, Its Debt-to-Equity ratio is 0.34 whereas as Long-Term Debt/Eq ratio is at 0.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on September 03, 2025, initiated with a Overweight rating and assigned the stock a target price of $31.
On July 21, 2025, Truist started tracking the stock assigning a Buy rating and target price of $30.Truist initiated its Buy rating on July 21, 2025, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 15 ’25 when HUSSAIN IQBAL J sold 6,000 shares for $17.23 per share. The transaction valued at 103,380 led to the insider holds 105,386 shares of the business.
HUSSAIN IQBAL J bought 6,000 shares of CNTA for $103,380 on Aug 15 ’25. On Jul 29 ’25, another insider, Accardi Mario Alberto, who serves as the President, Orexin Program of the company, sold 8,322 shares for $15.23 each. As a result, the insider received 126,751 and left with 208,163 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNTA now has a Market Capitalization of 2117012608 and an Enterprise Value of 1984436608. For the stock, the TTM Price-to-Sale (P/S) ratio is 140.40 while its Price-to-Book (P/B) ratio in mrq is 6.13. Its current Enterprise Value per Revenue stands at 132.296 whereas that against EBITDA is -9.628.
Stock Price History:
The Beta on a monthly basis for CNTA is 1.49, which has changed by 0.10419583 over the last 52 weeks, in comparison to a change of 0.20221436 over the same period for the S&P500. Over the past 52 weeks, CNTA has reached a high of $19.09, while it has fallen to a 52-week low of $9.60. The 50-Day Moving Average of the stock is -0.31%, while the 200-Day Moving Average is calculated to be 3.36%.
Shares Statistics:
The stock has traded on average 1.14M shares per day over the past 3-months and 1078390 shares per day over the last 10 days, according to various share statistics. A total of 133.91M shares are outstanding, with a floating share count of 85.14M. Insiders hold about 36.42% of the company’s shares, while institutions hold 56.11% stake in the company. Shares short for CNTA as of 1755216000 were 4645019 with a Short Ratio of 4.07, compared to 1752537600 on 3674823. Therefore, it implies a Short% of Shares Outstanding of 4645019 and a Short% of Float of 4.0799997999999995.
Earnings Estimates
Its stock is currently analyzed by 8.0 different market analysts. The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.38 and low estimates of -$0.51.
Analysts are recommending an EPS of between -$1.29 and -$1.46 for the fiscal current year, implying an average EPS of -$1.37. EPS for the following year is -$1.64, with 9.0 analysts recommending between -$1.37 and -$2.03.
